ChiCTR2500100535 版本V1.0 版本创建时间2025/04/10 15:54:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500100535 

最近更新日期:

Date of Last Refreshed on:

2025-04-10 15:54:01 

注册时间:

Date of Registration:

2025-04-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

可吸收接骨螺钉在中国人群手足部骨固定中的有效性及安全性的前瞻性、单中心、单臂临床研究

Public title:

A prospective, single-center, single-arm clinical study of the efficacy and safety of absorbable bone screws for bone fixation of the hand and foot in a Chinese population

注册题目简写:

English Acronym:

研究课题的正式科学名称:

可吸收接骨螺钉在中国人群手足部骨固定中的有效性及安全性的前瞻性、单中心、单臂临床研究

Scientific title:

A prospective, single-center, single-arm clinical study of the efficacy and safety of absorbable bone screws for bone fixation of the hand and foot in a Chinese population

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘鉴锋 

研究负责人:

刘彬 

Applicant:

Liu Jianfeng 

Study leader:

Liu Bin 

申请注册联系人电话:

Applicant telephone:

+86 18186872813

研究负责人电话:

Study leader's
telephone:

+86 431 88788009

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

storm1359@jlu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

kjkliubin@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

吉林省长春市朝阳区新民大街1号

研究负责人通讯地址:

新民大街1号、71号、大兴路2号、东民主大街519号、云鹤街15号、明德路48号、吉林大路3302号、安乐路2095号

Applicant address:

No. 1 Xinmin Street, Chaoyang District, Changchun City, Jilin Province, China

Study leader's address:

No. 1 and 71 Xinmin Street, No. 2 Daxing Road, No. 519 East Minzhu Street, No. 15 Yunhe Street, No. 48 Mingde Road, No. 3302 Jilin Road, No. 2095 Anle Road

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

吉林大学第一医院

Applicant's institution:

The First Hospital of Jilin University

研究负责人所在单位:

吉林大学第一医院

Affiliation of the Leader:

The First Hospital of Jilin University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

25K051-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

吉林大学第一医院伦理委员会

Name of the ethic committee:

The IRB of the First Hospital of Jilin University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-02-26 00:00:00

伦理委员会联系人:

赵丽媛

Contact Name of the ethic committee:

Zhao LiYuan

伦理委员会联系地址:

新民大街1号、71号、大兴路2号、东民主大街519号、云鹤街15号、明德路48号、吉林大路3302号、安乐路2095号

Contact Address of the ethic committee:

No. 1 and 71 Xinmin Street, No. 2 Daxing Road, No. 519 East Minzhu Street, No. 15 Yunhe Street, No. 48 Mingde Road, No. 3302 Jilin Road, No. 2095 Anle Road

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 431 88782013

伦理委员会联系人邮箱:

Contact email of the ethic committee:

18243006565@126.com

研究实施负责(组长)单位:

吉林大学第一医院

Primary sponsor:

The First Hospital of Jilin University

研究实施负责(组长)单位地址:

新民大街1号、71号、大兴路2号、东民主大街519号、云鹤街15号、明德路48号、吉林大路3302号、安乐路2095号

Primary sponsor's address:

No. 1 and 71 Xinmin Street, No. 2 Daxing Road, No. 519 East Minzhu Street, No. 15 Yunhe Street, No. 48 Mingde Road, No. 3302 Jilin Road, No. 2095 Anle Road

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

吉林

市(区县):

Country:

China

Province:

Jilin

City:

单位(医院):

吉林大学第一医院

具体地址:

新民大街1号、71号、大兴路2号、东民主大街519号、云鹤街15号、明德路48号、吉林大路3302号、安乐路2095号

Institution
hospital:

The First Hospital of Jilin University

Address:

No. 1 and 71 Xinmin Street, No. 2 Daxing Road, No. 519 East Minzhu Street, No. 15 Yunhe Street, No. 48 Mingde Road, No. 3302 Jilin Road, No. 2095 Anle Road

经费或物资来源:

诊疗装备与生物医用材料

Source(s) of funding:

National Key Research and Development Program of China

研究疾病:

需要进行手术的手足部骨折或融合的患者。  

Target disease:

Patients with fractures or fusions of the hand or foot requiring surgery.

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

单臂 

Study design:

Single arm 

研究目的:

主要研究目的:验证可吸收接骨螺钉用于治疗手足部骨折或融合的有效性。 次要研究目的:验证可吸收接骨螺钉用于治疗手足部骨折或融合的安全性。  

Objectives of Study:

primary study purpose: To validate the effectiveness of absorbable bone screws for the treatment of fractures or fusions of the hand and foot. Secondary study purpose: To validate the safety of absorbable bone screws for the treatment of hand and foot fractures or fusions.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄18~70周岁,男女均可;
2. 首次使用螺钉固定;
3. 需要进行手术的手足部骨折或融合的受试者;
4. 自愿参加并签署知情同意书。

Inclusion criteria

1. Age 18~70 years old, both male and female;
2. Screw fixing is used for the first time;
3. Subjects with fractures or fusions of the hand or foot requiring surgery;
4. Voluntary participation and signing of informed consent.

排除标准:

1. 骨病(良性或恶性肿瘤、结核、骨髓炎、内分泌代谢性等因素)所致的病理性骨折。
2. 解剖结构异常,骨干过度弯曲患者。
3. 预期植入物会承受高强度力学负荷。
4. 严重粉碎性骨折、骨质疏松使得植入物不能有效固定的情况。
5. 骨折局部软组织损伤和缺损,植入处无足够的组织覆盖。
6. 在骨髓炎症部位、化脓性感染部位、或者其他软组织感染部位。
7. 对植入材料疑似或已确认过敏的患者。
8. 存在麻醉及手术禁忌症者;
9. 妊娠及哺乳期女性;
10. 合并风湿免疫性疾病且对经研究者评估对试验结果评价存在影响者;
11. 存在感觉缺失且经研究者评估影响试验结果评价者;
12. 存在精神性疾病且经研究者评估对试验结果评价存在影响者。
13. 研究者认为可能存在增加受试者危险性或干扰临床试验的任何情况。

Exclusion criteria:

1. pathological fractures due to bone disease (benign or malignant tumors, tuberculosis, osteomyelitis, endocrine metabolic and other factors).
2. patients with anatomical anomalies and excessive bending of the diaphysis.
3. the implant is expected to be subjected to high mechanical loads.
4. severe comminuted fractures, osteoporosis that prevents effective fixation of the implant.
5. fractures with localized soft tissue damage and defects without adequate tissue coverage at the implant site.
6. at sites of bone marrow inflammation, septic infection, or other soft tissue infection.
7. patients with suspected or confirmed allergy to the implanted material.
8. Patients with contraindications to anesthesia and surgery;
9. Pregnant and breastfeeding women;
10. patients with co-morbid rheumatologic diseases that may affect the evaluation of the test results as assessed by the investigator;
11. the presence of sensory deficits which, as assessed by the investigator, affect the evaluation of the results of the test.
12. the presence of a psychiatric disorder that, in the opinion of the Investigator, affects the evaluation of the results of the trial.
13. any condition that, in the opinion of the Investigator, may increase the risk to the subject or interfere with the clinical trial.

研究实施时间:

Study execute time:

From 2025-03-15 00:00:00 To 2027-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-15 00:00:00 To 2025-10-15 00:00:00

干预措施:

Interventions:

组别:

可吸收接骨螺钉组

样本量:

60

Group:

Absorbable bone screw group

Sample size:

干预措施:

使用可吸收接骨螺钉进行骨固定

干预措施代码:

Intervention:

Bone fixation with absorbable bone screws

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

吉林 

市(区县):

 

Country:

China

Province:

Jilin

City:

单位(医院):

吉林大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Jilin University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术后6个月,手足部骨折或融合受试者的骨折愈合率。

指标类型:

主要指标

Outcome:

Fracture healing rates in subjects with hand and foot fractures or fusions at 6 months after surgery.

Type:

Primary indicator

测量时间点:

手术后6个月

测量方法:

将产品效果定义为以下3个等级:1.显效:骨折局部无压痛及纵向叩击痛,且DR显示骨折线模糊,有连续性骨痂通过骨折线。2.有效:骨折局部叩击存在轻微痛感,或DR显示骨折端骨痂较少,骨折线较明显。3.无效:骨折局部叩击存在明显痛感,或DR显示骨折线明显。 骨折愈合率计算方法:产品有效=显效+有效 骨折愈合率=产品有效的受试者数/受试者总数

Measure time point of outcome:

6 months after surgery

Measure method:

Calculation method of fracture healing rate: Effective = Effective + Effective Fracture healing rate = the number of subjects for whom the product is effective/total number of subjects.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

unshared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-04-10 15:54:01